{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(8)"],"submitter":["Salbach C"],"pubmed_abstract":["<h4>Background</h4>Guidelines of the European Society of Cardiology recommend a clinical risk assessment for patients with atrial fibrillation (AF). However, scores such as the CHA2DS2-VASc score show only a modest performance for prediction of adverse endpoints.<h4>Methods</h4>This retrospective single-center all-comer study uses data from the Heidelberg Registry of Atrial Fibrillation of 9,995 patients with non-valvular AF presenting to the emergency department (ED) of the University Hospital of Heidelberg from June 2009 until March 2020. Per CHA2DS2-VASc, risk was classified as low (0 point in men, ≤ 1 point in females), intermediate, or high (≥2 points in men and ≥3 points in females). The predictive performance of the CHA2DS2-VASc score, with and without highly sensitive cardiac troponin T (hs-cTnT), was evaluated for a composite endpoint comprising stroke, myocardial infarction (MI) or all-cause mortality.<h4>Results</h4>Performance of the CHA2DS2-VASc score for the prediction of the composite endpoint was poor Area under the curve (AUC): 0.648 (95%CI: 0.638-0.657) particularly in patients at intermediate-risk AUC: 0.542 (95%CI: 0.508-0.575). Adding hs-cTnT improved discrimination substantially in intermediate-risk patients (AUC: 0.778, 95% CI: 0.748-0.805). Notably, no events occurred in intermediate-risk patients with undetectable hs-cTnT (<5 ng/L).<h4>Conclusion</h4>In patients with AF at intermediate thromboembolic risk, the addition of hs-cTnT to the CHA₂DS₂-VASc score enhances prediction of adverse cardiovascular outcomes. Hs-cTnT may help identify patients who could benefit from anticoagulation, while also identifying a low-risk subgroup unlikely to experience events."],"journal":["PloS one"],"pagination":["e0330164"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12370022"],"repository":["biostudies-literature"],"pubmed_title":["Improvement in risk prediction for patients with atrial fibrillation and intermediate-risk CHA2DS2-VASc score utilizing highly sensitive cardiac troponin T."],"pmcid":["PMC12370022"],"pubmed_authors":["Mueller-Hennessen M","Salbach C","Katus H","Milles BR","Frey N","Hund H","Giannitsis E","Yildirim M"],"additional_accession":[]},"is_claimable":false,"name":"Improvement in risk prediction for patients with atrial fibrillation and intermediate-risk CHA2DS2-VASc score utilizing highly sensitive cardiac troponin T.","description":"<h4>Background</h4>Guidelines of the European Society of Cardiology recommend a clinical risk assessment for patients with atrial fibrillation (AF). However, scores such as the CHA2DS2-VASc score show only a modest performance for prediction of adverse endpoints.<h4>Methods</h4>This retrospective single-center all-comer study uses data from the Heidelberg Registry of Atrial Fibrillation of 9,995 patients with non-valvular AF presenting to the emergency department (ED) of the University Hospital of Heidelberg from June 2009 until March 2020. Per CHA2DS2-VASc, risk was classified as low (0 point in men, ≤ 1 point in females), intermediate, or high (≥2 points in men and ≥3 points in females). The predictive performance of the CHA2DS2-VASc score, with and without highly sensitive cardiac troponin T (hs-cTnT), was evaluated for a composite endpoint comprising stroke, myocardial infarction (MI) or all-cause mortality.<h4>Results</h4>Performance of the CHA2DS2-VASc score for the prediction of the composite endpoint was poor Area under the curve (AUC): 0.648 (95%CI: 0.638-0.657) particularly in patients at intermediate-risk AUC: 0.542 (95%CI: 0.508-0.575). Adding hs-cTnT improved discrimination substantially in intermediate-risk patients (AUC: 0.778, 95% CI: 0.748-0.805). Notably, no events occurred in intermediate-risk patients with undetectable hs-cTnT (<5 ng/L).<h4>Conclusion</h4>In patients with AF at intermediate thromboembolic risk, the addition of hs-cTnT to the CHA₂DS₂-VASc score enhances prediction of adverse cardiovascular outcomes. Hs-cTnT may help identify patients who could benefit from anticoagulation, while also identifying a low-risk subgroup unlikely to experience events.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-05-29T12:49:00.276Z","creation":"2026-04-08T04:49:08.844Z"},"accession":"S-EPMC12370022","cross_references":{"pubmed":["40839563"],"doi":["10.1371/journal.pone.0330164"]}}